Deletions Section 2 Cardiovascular June 2010 Vasodilator antihypertensive drugs - minoxidil, sodium nitroprusside. Centrally acting - clonidine Calcium Channel Blockers - Dihydropyridines - nifedipine Inotropic Sympathomimetics - dopexamine Oral anticoagulants - phenindione Antifibrinolytics - etamsylate Bile acid sequestrants - colestipol Dabigatran etexilate (Pradaxa®). Restricted use for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors. Restricted to patients in whom there is poor INR control with warfarin unrelated to compliance or in patients who are genuinely intolerant of warfarin/coumarins. Section 3 Respiratory June 2011
SABA choice - terbutaline removed. LABAs - Indacaterol moved to restricted list.
Cromoglicate and related therapy - no products recommended. Sodium cromoglicate, nedocromil sodium removed. Leukotriene receptor antagonists - zafirlukast removed.
Allergen immunotherapy - Omalizumab moved to restricted list. Respiratory stimulants and pulmonary surfactants moved to the restricted list.
Section 4 CNS February 2010
Sibutramine for treatment of obesity. Marketing authorisation suspended due to risk of cardiovascular adverse effects.
Instanyl® nasal spray. Preferred nasal spray formulation is PecFent®
Section 5 Infections June 2010 Antipseudomonal penicillins -Tazocin® (replaced with generic name). Cephalosporins - Cefaclor and cefuroxime for general use in primary care. Tetracyclines - Minocycline. Tetracycline Aminoglycosides - Neomycin Anti-tuberculous drugs - Rifabutin Rimactazid® Streptomycin Quinolones - Moxifloxacin Antifungal drugs - Flucytosine HIV Infection - Combivir®
Statement stating Famciclovir is not approved for genital herpes.
CMV Infection - Foscarnet Influenza - Amantadine RSV - Ribavarin Antimalarials - Primaquine Pneumocystis Pneumonia - Pentamidine Enfuviritide. In combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients. Section 6 Endocrine System April 2010
Vildagliptin (Galvus®). Treatment of type 2 diabetes mellitus in combination with metformin. Replaced by saxagliptin.
Rosiglitazone (Avandia®, Avandamet®). Treatment of type 2 diabetes mellitus.
Marketing authorisation suspended due to risk of cardiovascular adverse effects.
Section 7 Obstetrics, gynaecology and urinary tract disorders December 2010
Implanon® Contraceptive Implant. Replaced by Nexplanon®.
Section 9 Nutrition and Blood October 2011
Calcichew-D3®, Calfovit®, Calceos® Calcium and vitamin D preparations. Formulary choice for all formulations is Adcal-D3 range.
Section 10 Musculoskeletal October 2011
Coxibs - no longer recommended as formulary choices for any group of patients. Only to be used when at least 2 standard NSAIDs have been ineffective / not tolerated.
Topicasl NSAIDs - ketoprofen, Algesal, Movelat, Transvasin.
Section 11 Eye October 2009
Removal of non-specific second line agents i.e. gentamicin, polyfax, propamidine
Corticosteroids - Removed statement about prescribing in primary care on acute prescription only and reviewing every 2 months. Mydriatics - Removed homatropine as antimuscarinic choice
Beta-blockers - removed carteolol, levobunolol
Peri-operative preps. - Removal of flurbiprofen, acetylcholine chloride, apraclonidine. AMD - Removal of pegaptinib
Section 12 ENT March 2012
Fluticasone propionate nasal spray. Triamcinolone nasal spray Azelastine nasal spray Budesonide nasal spray
Adcortyl in Orabase Amphoteracin lozenges
Section 13 Skin December 2009
Medium weight emollients - Calmurid, Hydromol cream, Unguentum M
Bath additives - Aveeno, Hydromol. Barrier preps. - Epaderm
Rosacea Oral choices - Lymecycline, minocycline
Camouflagers - Covermark Cocois scalp ointment
Beter effect antidepressiva Suppletie foliumzuur bij gebruik fluoxetine door Ary van der Kuy, Lan Kiauw de Munck-Khoe - 05-10-2012 Foliumzuur verbetert vaak de respons op fluoxetine en andere antidepressiva bij therapieresistente patiënten. Foliumzuur is nodig voor de synthese van monoamine-neurotransmitters. • Casus Een 54-jarige man met de diagnose ernstige depressie, zonder p